APA (7th ed.) Citation

Bohm, M., Xu, R., Zhang, Y., Varma, S., Fischer, M., Kochhar, G., . . . Kane, S. (2020). Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Alimentary Pharmacology & Therapeutics, 52(4), 669. https://doi.org/10.1111/apt.15921

Chicago Style (17th ed.) Citation

Bohm, Matthew, et al. "Comparative Safety and Effectiveness of Vedolizumab to Tumour Necrosis Factor Antagonist Therapy for Crohn's Disease." Alimentary Pharmacology & Therapeutics 52, no. 4 (2020): 669. https://doi.org/10.1111/apt.15921.

MLA (9th ed.) Citation

Bohm, Matthew, et al. "Comparative Safety and Effectiveness of Vedolizumab to Tumour Necrosis Factor Antagonist Therapy for Crohn's Disease." Alimentary Pharmacology & Therapeutics, vol. 52, no. 4, 2020, p. 669, https://doi.org/10.1111/apt.15921.